[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334685-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334685-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","pan-cancer-analysis-reveals-interleukin-32-il32-is-a-potential-prognostic-and-immunotherapeutic-biomarker-in-cancer-research-paper","Pan-cancer analysis reveals - Interleukin 32 (IL32) is a potential prognostic and immunotherapeutic biomarker in cancer - research paper","","Interleukin 32 (IL32) is a pro-inflammatory cytokine linked to sterile inflammation, yet its roles across cancers are insufficiently defined. This study mines multiple public datasets (TCGA, GTEx, cBioPortal, GDC) to connect IL32 expression with genomic features and clinical outcomes in a pan-cancer setting. IL32 expression is higher in tumors than normal tissue and correlates with poor overall survival. IL32 associates with immune infiltration, stemness, TMB, MSI, immune checkpoints, and enriched cancer-related pathways.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/pan-cancer-analysis-reveals-interleukin-32-il32-is-a-potential-prognostic-and-immunotherapeutic-biomarker-in-cancer-research-paper/334685/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/pan-cancer-analysis-reveals-interleukin-32-il32-is-a-potential-prognostic-and-immunotherapeutic-biomarker-in-cancer-research-paper/334685.png","ImageObject",300,407,{"name":42,"@type":43},"Olivia Brown","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main aim of the study on IL32?","Question",{"text":63,"@type":64},"To investigate how IL32 expression relates to immunity and to map its prognostic landscape across multiple cancers using pan-cancer data mining and visualization.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do tumor IL32 expression levels compare with normal tissues?",{"text":68,"@type":64},"Tumor tissues show higher IL32 expression levels than normal tissues.",{"name":70,"@type":61,"acceptedAnswer":71},"Which factors are reported to correlate with IL32 expression in cancers?",{"text":72,"@type":64},"IL32 expression is associated with tumor stemness, TMB, MSI, immune checkpoint genes, and the infiltration levels of several immune cell types, including B cells, CD4 T cells, CD8 T cells, neutrophils, macrophages, and dendritic cells.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334685,1790430198,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nPan‑cancer analysis reveals  \nIL32 is a potential prognostic and immunotherapeutic biomarker in cancer  \nFeng Han & Jianxin Ma *  \nInterleukin 32 (IL32) is a pro‑inflammatory cytokine that plays a key role in promoting sterile inflammation by modulating immune responses. However, the role of IL32 in various cancers remains unclear. This research aimed to investigate the correlation between IL32 expression and immunity and visualize its prognostic landscape in pan‑cancer. We investigated gene expression, genomic alterations, and survival analysis of IL32 in pan‑cancer in numerous databases including TCGA, GTEx, cBioPortal, and GDC databases. Tumor immune cell infiltration was assessed using the CIBERSORT computational method as well as the ESTIMATE method to analyze the correlation of IL32 expression with stromal and immune components. Protein–protein interaction analysis was performed in the STRING and GeneMANIA databases, and gene function enrichment was performed by GO set enrichment analysis. Tumor tissues had higher IL32 expression levels than normal tissues. Elevated IL32 expression was associated with poor OS and prognosis. In addition, tumor stemness, TMB, MSI, and immune checkpoint genes were also associated with IL32 expression. Correlations were observed between IL32 expression and B cell, CD4T cell, CD8T cell, neutrophil, macrophage, and DC infiltration in multiple cancers. GO enrichment analysis showed that IL32 expression was associated with cancer pathways, cytokine‑receptor interactions, and NOD‑like receptor signaling pathways. These findings suggest that IL32 may serve as a biomarker of cancer immune infiltration and poor prognosis, providing new therapeutic targets for cancer treatment.  \nThe development of malignant tumors is related to a variety offactors, and monitoring tumor occurrence, early prevention, and timely control of tumors is important for human health1,2. Inflammation plays a crucial role in carcinogenesis and affects the development of malignant tumors and invasive metastasis. Interleukin-32 (IL-32), a newly identified pro-inflammatory cytokine, can be involved in the development of inflammatory diseases anda variety of malignancies1. IL-32 was initially identified in activated natural killer (NK) and T cells, and its expression was strongly enhanced by microbes, mitogens, and other pro-inflammatory cytokines2. Increasing evidence suggests that IL-32 acts as an amplifier of inflammation through its stimulatory effects on pro-inflammatory cytokines, including IL-1β, IL-6, and tumor necrosis factor-alpha (TNF-a) . IL-32 is commonly used as a proinflammatory cytokine and is highly expressed in inflammatory disorders and a variety of malignant tumors, where it induces the release of cytokines, which are important for the formation of the inflammatory microenvironment and promote the growth, migration, and invasion of tumor cells3,4. The inflammatory microenvironment plays a crucial role in tumorigenesis, and targeting the inflammatory microenvironment has preventive and therapeutic implications for a variety of tumors.  \nIn recent years, the analysis of tumorigenesis and progression in pan-cancer has been increasingly studied. Pan-carcinoma analysis allows the analysis of genes in multiple cancers, in which differences and similarities in the expression of extracted genes are compared5, revealing similarities and differences in cancers and mining valuable factors for diagnosis, prognosis, and immunotherapy6. Therefore, it is meaningful to further explore the pan-carcinogenic gene profiles. To date, the role of IL32 in pan-cancer remains uncertain. In the present study, based on data mining analysis of various databases, we comprehensively analyzed the expression of IL32 and its association with tumor-infiltrating immune cells and related immune markers and further evaluated the prognostic value of IL32 in predicting su","cbCairoEOl9l1E1z","https://ap.wps.com/l/cbCairoEOl9l1E1z","pdf",3607627,15,"English","# Methods\n## Data source and processing\n## Analysis of gene expression\n## Gene alteration analysis","[{\"question\":\"What was the main aim of the study on IL32?\",\"answer\":\"To investigate how IL32 expression relates to immunity and to map its prognostic landscape across multiple cancers using pan-cancer data mining and visualization.\"},{\"question\":\"How do tumor IL32 expression levels compare with normal tissues?\",\"answer\":\"Tumor tissues show higher IL32 expression levels than normal tissues.\"},{\"question\":\"Which factors are reported to correlate with IL32 expression in cancers?\",\"answer\":\"IL32 expression is associated with tumor stemness, TMB, MSI, immune checkpoint genes, and the infiltration levels of several immune cell types, including B cells, CD4 T cells, CD8 T cells, neutrophils, macrophages, and dendritic cells.\"}]","Pan-cancer analysis reveals - Interleukin 32 (IL32) is a potential prognostic and immunotherapeutic biomarker in cancer - research paper | PDF",1790007848,38]